Entrada Therapeutics Stock Analysis

Entrada Stock Analysis Notes

About 13.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.6. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Entrada Therapeutics had not issued any dividends in recent years. Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle therapeutics for the treatment of multiple neuromuscular diseases. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. Entrada Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people. To find out more about Entrada Therapeutics contact Dipal Doshi at 857 520 9158 or learn more at https://www.entradatx.com.

Entrada Therapeutics Investment Alerts

Entrada Therapeutics Upcoming and Recent Events

Entrada Largest EPS Surprises

View All Earnings Estimates

Entrada Therapeutics Environmental, Social, and Governance (ESG) Scores

Entrada Stock Institutional Investors

Note, although Entrada Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Entrada Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 675.43 M.

Entrada Profitablity

The company has Profit Margin (PM) of 0.26 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (1.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.11.

Management Efficiency

Entrada Therapeutics has return on total asset (ROA) of 0.0695 % which means that it generated a profit of $0.0695 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1642 %, meaning that it created $0.1642 on every $100 dollars invested by stockholders. Entrada Therapeutics' management efficiency ratios could be used to measure how well Entrada Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.01. In addition to that, Return On Capital Employed is expected to decline to -0.01. At present, Entrada Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 7.1 M, whereas Total Assets are forecasted to decline to about 239.5 M.

Technical Drivers

As of the 23rd of November, Entrada Therapeutics shows the Mean Deviation of 2.36, coefficient of variation of 1701.79, and Downside Deviation of 3.09. In respect to fundamental indicators, the technical analysis model provides you with a way to check existing technical drivers of Entrada Therapeutics, as well as the relationship between them.

Entrada Therapeutics Price Movement Analysis

Entrada Therapeutics Insider Trading Activities

Entrada Therapeutics Outstanding Bonds

Entrada Therapeutics Predictive Daily Indicators

Entrada Therapeutics Corporate Filings

Entrada Therapeutics Forecast Models

Entrada Therapeutics' time-series forecasting models are one of many Entrada Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Entrada Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Entrada Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Entrada shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Entrada Therapeutics. By using and applying Entrada Stock analysis, traders can create a robust methodology for identifying Entrada entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Entrada analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Entrada analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Entrada Therapeutics stock analysis indicators help investors evaluate how Entrada Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Entrada Therapeutics shares will generate the highest return on investment. By understating and applying Entrada Therapeutics stock analysis, traders can identify Entrada Therapeutics position entry and exit signals to maximize returns.

When running Entrada Therapeutics' price analysis, check to measure Entrada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entrada Therapeutics is operating at the current time. Most of Entrada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Entrada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entrada Therapeutics' price. Additionally, you may evaluate how the addition of Entrada Therapeutics to your portfolios can decrease your overall portfolio volatility.